Sionna Therapeutics to Participate in Upcoming September Investor Conferences
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3rd at 1:35 p.m. ET and the Morgan Stanley Global Healthcare Conference on September 8th at 7:00 a.m. ET. Both events will be held in New York and will be available via webcast on the company's investor relations website.
Sionna Therapeutics (NASDAQ:SION), azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per la fibrosi cistica, ha comunicato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a settembre 2025.
La società prenderà parte a discussioni informali (fireside chats) al Cantor Global Healthcare Conference il 3 settembre alle 13:35 ET e al Morgan Stanley Global Healthcare Conference l'8 settembre alle 7:00 ET. Entrambi gli eventi si terranno a New York e saranno trasmessi via webcast sul sito degli investor relations dell'azienda.
Sionna Therapeutics (NASDAQ:SION), una compañía biofarmacéutica en fase clínica centrada en tratamientos para la fibrosis quística, ha anunciado su participación en dos importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La empresa participará en charlas tipo "fireside" en el Cantor Global Healthcare Conference el 3 de septiembre a las 13:35 ET y en el Morgan Stanley Global Healthcare Conference el 8 de septiembre a las 7:00 ET. Ambos eventos tendrán lugar en Nueva York y estarán disponibles por webcast en la web de relaciones con inversores de la compañía.
Sionna Therapeutics (NASDAQ:SION), 낭포성 섬유증 치료제 개발에 주력하는 임상 단계 바이오제약사로, 2025년 9월 열리는 두 건의 주요 헬스케어 투자자 컨퍼런스에 참가한다고 밝혔다.
회사는 Cantor Global Healthcare Conference에서 9월 3일 오후 1시 35분(동부시간)과 Morgan Stanley Global Healthcare Conference에서 9월 8일 오전 7시(동부시간)에 파이어사이드 챗에 참여할 예정이다. 두 행사는 뉴욕에서 개최되며 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있다.
Sionna Therapeutics (NASDAQ:SION), société biopharmaceutique en phase clinique spécialisée dans le développement de traitements pour la mucoviscidose, a annoncé sa participation à deux grandes conférences destinées aux investisseurs en santé en septembre 2025.
La société prendra part à des "fireside chats" lors du Cantor Global Healthcare Conference le 3 septembre à 13h35 ET et du Morgan Stanley Global Healthcare Conference le 8 septembre à 07h00 ET. Les deux événements se tiendront à New York et seront diffusés en webcast sur le site relations investisseurs de la société.
Sionna Therapeutics (NASDAQ:SION), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Therapien für Mukoviszidose entwickelt, hat seine Teilnahme an zwei wichtigen Healthcare-Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an sogenannten Fireside Chats beim Cantor Global Healthcare Conference am 3. September um 13:35 Uhr ET und beim Morgan Stanley Global Healthcare Conference am 8. September um 07:00 Uhr ET teilnehmen. Beide Veranstaltungen finden in New York statt und werden per Webcast auf der Investor-Relations-Webseite des Unternehmens verfügbar sein.
- None.
- None.
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:
- Cantor Global Healthcare Conference 2025 in New York, NY on Wednesday, September 3rd, 2025, at 1:35 p.m. ET; and
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on Monday, September 8th, 2025, at 7:00 a.m. ET.
Live webcasts of the presentations will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available following the event.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When is Sionna Therapeutics (SION) presenting at the Cantor Global Healthcare Conference 2025?
What time is Sionna Therapeutics' presentation at the Morgan Stanley Healthcare Conference 2025?
Where can I watch Sionna Therapeutics' (SION) investor conference presentations?
What is Sionna Therapeutics' (SION) main focus in drug development?
